Leipzig / Nuremberg, – Just over a year ago, on 27 August 2018, the European Commission gave their approval for the CAR-T cells developed by Novartis to be used in Germany.
In Germany, more than 15 hospitals 1 are now certified to carry out the CAR-T cell therapy developed by Novartis. Each patient-specific CAR-T cell infusion is the result of an individualized, innovative manufacturing and logistics process that Novartis has established together with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig. Around one year ago, the European Commission approved the use of Novartis’ CAR-T cells in Germany for patients diagnosed with certain types of life-threatening blood cancer who have extremely limited survival prospects. Preclinical testing of a ATMP for the treatment of knee cartilage damage completed. Fraunhofer IZI and BioNTech to collaborate in the future. Fraunhofer Center MEOS becomes technology hub for cell-based therapeutics in Thuringia. Activation of the aryl hydrocarbon receptor (AhR) has an anti-inflammatory effect. New Fraunhofer Center for Digital Diagnostics. Fraunhofer opens up prospects in structurally weak regions. Fraunhofer IZI and Nomad Bioscience extend and broaden collaboration. Researchers want to filter and inactivate airborne pathogens using tissue. Anhalt University of Applied Sciences and Fraunhofer IZI open joint research laboratory for natural product-based therapeutics. Simplified method developed for monitoring CAR T-cell therapies using flow cytometry. Researchers aim at developing a vaccine protecting against urinary tract infection. Fraunhofer Prize for Human- and Environment-Centered Technology 2021. Periodontitis: Researchers search for a new active substance. SaxoCell – “living drug” Made in Saxony. Optimization of novel immune cell therapies. Rapid diagnostic device for trachoma eye infection delivers first promising result. Fraunhofer IZI presents new technologies and services for the healthcare industry at the Fraunhofer Solution Days. Viromers suitable as carrier systems for gene-based treatment of inflammatory diseases. Fraunhofer IZI cooperates with Nomad Bioscience to develop novel anti-bacterial and anti-viral medications. Fraunhofer relies on Automation Technologies in Medical Research. A chemical tailor-made suit for Alzheimer’s drugs. Prognostic biomarkers for prostate cancer identified. Astacin Proteases Unit established at Fraunhofer IZI. Patented Fraunhofer IZI technology facilitates specific Dengue virus diagnostics. Professor Ulrich Demuth appointed to the German Ethics Council. Pathogen of Q fever detected in the feces of ticks. 
Hitchhiker’s Guide to the Cell: Fraunhofer IZI researches to improve imaging methods for organoids.Development of therapeutic antibodies for HERV-associated autoimmune and tumor diseases.
0 kommentar(er)
